A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 microg) Delivered Via the HandiHaler in Patients With Newly Diagnosed and/or Maintenance Treatment naive Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection

Trial Profile

A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 microg) Delivered Via the HandiHaler in Patients With Newly Diagnosed and/or Maintenance Treatment naive Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2014

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms TICARI 1
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 May 2012 Planned end date changed from 1 Aug 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top